Sprint Bioscience is looking to replace Decipher as a partner for VPS34 as soon as the project is handed back. Decipher’s decision follows four month after securing Day One as a partner for VADA. We have made an early revision where the main change is a 15-24 months delay for the VPS34 project. We point to upcoming triggers relating to VADA and NASH. We adjust our base case to SEK3.2 (SEK3.9).

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

© Modular Finance, source Nordic Press Releases